1.Topical fibronectin treatment in persistent corneal epithelial defects and corneal ulcers.
Ki San KIM ; Joon Sup OH ; In San KIM ; Joon Sung JO
Korean Journal of Ophthalmology 1990;4(1):5-11
Topical fibronectin, autologous and homologous, was used to treat nine patients (eleven eyes) with persistent corneal epithelial defects and corneal ulcers that failed to improve with standard therapy. The fibronectin was purified from autologous and homologous plasma by gelatin-Sepharose 4B affinity chromatography and administered topically, 500 micrograms/ml five times a day, for three weeks. Complete or nearly complete reepithelialization was achieved in all patients regardless of the source of fibronectin, autologous or homologous. But healing times varied. The average healing time was 41.7 +/- 14.7 days (35.7 +/- 12.4 days for autologous, 50.8 +/-14.4 days for homologous). Ocular symptoms were relieved significantly, and no side effects were observed. Over an average follow-up period of 5.2 months, no recurrences were noted. The results showed that homologous, as well as autologous, fibronectin was effective in patients with persistent corneal epithelial defects and corneal ulcers.
Administration, Topical
;
Adult
;
Aged
;
Blood Proteins/isolation & purification
;
Chromatography, Affinity
;
Corneal Diseases/*drug therapy
;
Corneal Ulcer/*drug therapy
;
Epithelium/drug effects
;
Female
;
Fibronectins/administration & dosage/isolation & purification/*therapeutic use
;
Humans
;
Male
;
Middle Aged
;
Visual Acuity
;
Wound Healing/drug effects
3.The Changes in Corneal Astigmatism after Botulinum Toxin-A Injection in Patients with Blepharospasm.
Nam Ju MOON ; Hyeon Il LEE ; Jae Chan KIM
Journal of Korean Medical Science 2006;21(1):131-135
To determine if the involuntary contractions of eyelids may have any effects on the development of corneal astigmatism, we performed this prospective study which includes 19 patients with either essential blepharospasm or hemifacial spasm. In hemifacial spasm, the degree of corneal astigmatism was evaluated between two eyes. Then the topographic changes were checked using vector analysis technique before and after passively opening the eyelids. They were also measured before and at 1 and 6 months after the injection of Botulinum toxin. Resultantly, 20 eyes had the with-the-rule (group1) and 9 eyes against-the-rule (group2) astigmatism. In hemifacial spasm, significantly more astigmatism was found at spastic eyes. The corneal topographic changes after passively opening the eyelids showed 10 eyes with the astigmatic shift to the with-the-rule, while the remaining 19 to the againstthe- rule. At 1 month after injection of Botulinum toxin, group 1 showed reduced average corneal astigmatism, whereas group 2 showed increased astigmatism. The astigmatic change vector showed significantly more against-the-rule. In the contrary, 6 months after treatment, corneal astigmatism again increased in group 1 and decreased in group 2. So they took on the appearance of pretreatment astigmatic status eventually. Conclusively eyelids may play an important role in corneal curvature.
Aged
;
Astigmatism/*drug therapy/physiopathology
;
Blepharospasm/*drug therapy/physiopathology
;
Botulinum Toxin Type A/administration & dosage/*therapeutic use
;
Cornea/drug effects/physiopathology
;
Corneal Diseases/*drug therapy/physiopathology
;
Eyelids/drug effects/physiopathology
;
Female
;
Humans
;
Injections
;
Male
;
Middle Aged
;
Time Factors
;
Treatment Outcome
4.Acetazolamide for Cystoid Macular Oedema in Bietti Crystalline Retinal Dystrophy.
Geoffrey K BROADHEAD ; Andrew A CHANG
Korean Journal of Ophthalmology 2014;28(2):189-191
Bietti crystalline retinal dystrophy is a rare, inherited disorder whose hallmark is the presence of retinal crystal deposits associated with later chorioretinal degeneration. This condition may rarely be complicated by the development of cystoid macular oedema leading to rapid visual decline. Currently, treatment options for this complication of Bietti dystrophy are limited and the visual prognosis is poor. Here, we present a case of cystoid macular oedema associated with Bietti dystrophy that was successfully diagnosed using multimodal imaging techniques including optical coherence tomography and fluorescein angiography. These modalities confirmed the diagnosis of macular oedema and excluded other possible causes of oedema such as choroidal neovascularisation. In this patient, cystoid macular oedema was resolved with oral acetazolamide therapy, a treatment that has not been previously reported in this context. Acetazolamide treatment resulted in oedema resolution and improvement in visual function, and can be considered a therapeutic option for other patients with Bietti dystrophy who develop cystoid macular oedema.
Acetazolamide/*administration & dosage
;
Administration, Oral
;
Adult
;
Corneal Dystrophies, Hereditary/*drug therapy/pathology
;
Diuretics/*administration & dosage
;
Humans
;
Macular Edema/*drug therapy/pathology
;
Male
;
Retinal Diseases/*drug therapy/pathology
;
Tomography, Optical Coherence
;
Treatment Outcome
5.Combined Treatment for Band Keratopathy.
Journal of Korean Medical Science 2004;19(6):915-916
No abstract available.
*Biological Dressings
;
Calcinosis/complications/*drug therapy
;
Chelating Agents/*therapeutic use
;
Chelation Therapy/*methods
;
Child
;
Child, Preschool
;
Clinical Trials
;
Combined Modality Therapy
;
Corneal Diseases/*drug therapy/etiology/*surgery
;
Edetic Acid/*therapeutic use
;
Humans
;
Keratectomy, Laser/*methods
6.New Treatment for Band Keratopathy: Superficial Lamellar Keratectomy, EDTA Chelation and Amniotic Membrane Transplantation.
Young Sam KWON ; Young Soo SONG ; Jae Chan KIM
Journal of Korean Medical Science 2004;19(4):611-615
We report two cases of band keratopathy who were treated with thick amniotic membrane that contained a basement membrane structure as a graft, after ethylenediaminetetraacetic acid chelation with trephination and blunt superficial lamellar keratectomy in the anterior stroma. In each case, basement membrane was destroyed and calcium plaque invaded into anterior stroma beneath Bowman's membrane. The calcified lesions were removed surgically, resulting in a smooth ocular surface, and the fine structures of band keratopathy were confirmed by pathologic findings. After that, amniotic membrane transplantation was performed to replace the excised epithelium and stroma. Wound healing was completed within 10 days. Stable ocular surface was restored without pain or inflammation. During the mean follow-up period of 13.5 months, no recurrence of band keratopathy was observed. This combined treatment is a safe and effective method for the removal of deep-situated calcium plaque and allowing the recovery of a stable ocular surface.
Amnion/*anatomy & histology/*transplantation
;
Calcium/metabolism
;
Chelating Agents/*therapeutic use
;
Cornea/pathology/surgery
;
Corneal Diseases/*drug therapy/pathology/*surgery
;
Edetic Acid/*therapeutic use
;
Female
;
Humans
;
Male
;
Middle Aged
7.Methotrimeprazine-induced Corneal Deposits and Cataract Revealed by Urine Drug Profiling Test.
Seong Taeck KIM ; Jae Woong KOH ; Joon Mo KIM ; Won Young KIM ; Gwang Ju CHOI
Journal of Korean Medical Science 2010;25(11):1688-1691
Two schizophrenic patients who had been taking medication for a long period presented with visual disturbance of 6-month duration. Slit-lamp examination revealed fine, discrete, and brownish deposits on the posterior cornea. In addition, bilateral star-shaped anterior subcapsular lens opacities, which were dense, dust-like granular deposits, were noted. Although we strongly suspected that the patient might have taken one of the drugs of the phenothiazine family, we were unable to obtain a history of medications other than haloperidol and risperidone, which were taken for 3 yr. We performed a drug profiling test using urine samples and detected methotrimeprazine. The patient underwent surgery for anterior subcapsular lens opacities. Visual acuity improved in both eyes, but the corneal deposits remained. We report an unusual case of methotrimeprazine-induced corneal deposits and cataract in a patient with psychosis, identified by using the urine drug profiling test.
Adult
;
Antipsychotic Agents/*adverse effects/therapeutic use/urine
;
Cataract/*chemically induced
;
Corneal Diseases/*chemically induced
;
Female
;
Humans
;
Male
;
Mental Retardation/diagnosis/drug therapy
;
Methotrimeprazine/*adverse effects/therapeutic use/urine
;
Middle Aged
;
Schizophrenia/diagnosis/drug therapy
;
Visual Acuity
8.Clinical efficacy of topical homologous fibronectin in persistent corneal epithelial disorders.
Ki San KIM ; Joon Sup OH ; In San KIM ; Joon Sung JO
Korean Journal of Ophthalmology 1992;6(1):12-18
The clinical efficacy was investigated of topical homologous fibronectin on persistent corneal epithelial defects of various etiologies. Fibronectin was purified from blood bank homologous plasma by gelatin-Sepharose 4B affinity chromatography. Twenty eight eyes of twenty five patients with persistent corneal epithelial defects and sterile corneal ulcers that failed to improve with standard therapy were treated by the instillation of homologous fibronectin eyedrops 5 times a day (500 microgram/ml). Complete reepithelialization was achieved in all patients except two eyes due to uncontrolled glaucoma and the taking of steroids. The healing time tended to be different depending on the duration of persistent corneal epithelial defects and the severity of underlying diseases. The mean +/- standard deviation duration of epithelial defect was 68.18 +/- 77.80 days. Average healing time was 42.07 +/- 17.47 days. Ocular symptoms were relieved significantly and no side effects were observed. Over an average follow-up period of about 8 months, two cases of recurrences were noted. These results show that homologous fibronectin was also effective in patients with persistent corneal epithelial defects and corneal ulcers.
Administration, Topical
;
Adult
;
Aged
;
Child
;
Corneal Diseases/blood/*drug therapy
;
Epithelium/drug effects
;
Female
;
Fibronectins/blood/*therapeutic use
;
Humans
;
Infant
;
Male
;
Middle Aged
;
Ophthalmic Solutions/therapeutic use
;
Wound Healing/drug effects
9.Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer.
Jeeyun AHN ; Won Ryang WEE ; Jin Hak LEE ; Joon Young HYON
Korean Journal of Ophthalmology 2011;25(5):355-357
We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this corneal complication.
Adult
;
Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
;
Cornea/drug effects/*pathology
;
Corneal Diseases/*chemically induced/diagnosis
;
Diagnosis, Differential
;
Dose-Response Relationship, Drug
;
Female
;
Follow-Up Studies
;
Humans
;
Lung Neoplasms/*drug therapy/pathology
;
Microscopy, Acoustic
;
Piperidines/administration & dosage/*adverse effects
;
Quinazolines/administration & dosage/*adverse effects
;
Visual Acuity